Related Experiment Video

Updated: Jun 5, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Statins and dilated cardiomyopathy: do we have enough data?

Agata Bielecka-Dabrowa1, Dimitri P Mikhailidis, Simon Hannam

  • 1Medical University of Lodz, Department of Hypertension, Zeromskiego 113, Lodz 90-549, Poland.

Expert Opinion on Investigational Drugs
|January 8, 2011
PubMed

Insights

Statins may improve left ventricular function and exercise tolerance in dilated cardiomyopathy (DCM) patients by reducing inflammation and endothelial damage. Eligible DCM patients should be in NYHA class II or III with normal or elevated lipid levels.

Area of Science:

  • Cardiology
  • Pharmacology
  • Immunology

Background:

  • Dilated cardiomyopathy (DCM) involves ventricular enlargement and systolic dysfunction, leading to congestive heart failure (CHF).
  • Current CHF treatments do not fully address underlying pathogenic mechanisms, contributing to high morbidity and mortality.
  • Inflammation is implicated in CHF progression, affecting cardiac contractility, hypertrophy, apoptosis, and remodeling.

Purpose of the Study:

  • To explore the potential role of statins in managing DCM and CHF.
  • To investigate the mechanisms by which statins might improve cardiac function in DCM patients.

Main Methods:

  • Systematic literature search of MEDLINE, EMBASE, SCOPUS, and DARE databases (1966-2010).
  • Inclusion of abstracts from national and international cardiovascular meetings.
  • Search terms included dilated cardiomyopathy, dyslipidemia, heart failure, left ventricle dysfunction, and statins.

Main Results:

  • Evidence suggests inflammation contributes to DCM and CHF progression.
  • Immunomodulating treatments like statins show promise in cardiomyopathy patients.
  • Potential mechanisms include inflammation inhibition, alleviation of endothelial damage, and reduction of endothelial dysfunction.

Conclusions:

  • Inhibiting inflammation and improving endothelial function may enhance left ventricular function and exercise tolerance in DCM.
  • Statins are potential candidates for DCM patients in New York Heart Association class II or III with normal or elevated lipid levels.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...